These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9394998)

  • 41. Photosensitivity from oral administration of a fluorouracil derivative (FT 207).
    Sun CC; Hsu SC
    Photodermatol; 1984 Apr; 1(2):94-5. PubMed ID: 6442417
    [No Abstract]   [Full Text] [Related]  

  • 42. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil and oteracil potassium) for colorectal cancer.
    Kawahara H; Watanabe K; Ushigome T; Noaki R; Kobayashi S; Yanaga K
    Hepatogastroenterology; 2012; 59(113):134-7. PubMed ID: 22251528
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [A Case of Subacute Thyroiditis during Chemotherapy after Distal Pancreatectomy].
    Saito Y; Hara H; Tsujie M; Miyamoto A; Asaoka T; Yamamoto K; Ikenaga M; Miyazaki M; Ikeda M; Hirao M; Fujitani K; Sekimoto M; Nakamori S
    Gan To Kagaku Ryoho; 2016 May; 43(5):621-3. PubMed ID: 27210095
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Evaluation of tegafur encapsulated with slow-releasing granules (SF-SP) for patients with cancer of the digestive organs].
    Kameda C; Tanaka T; Shiomi M; Saka M; Katsu K; Itoh S
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2526-30. PubMed ID: 6439120
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy.
    Fang WJ; Mou HB; Jin DZ; Zheng YL; Zhao P; Mao CY; Peng L; Huang MZ; Xu N
    Oncol Rep; 2012 May; 27(5):1606-10. PubMed ID: 22322240
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer.
    Kinoshita T; Nashimoto A; Yamamura Y; Okamura T; Sasako M; Sakamoto J; Kojima H; Hiratsuka M; Arai K; Sairenji M; Fukushima N; Kimura H; Nakajima T
    Gastric Cancer; 2004; 7(2):104-9. PubMed ID: 15224197
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Tegafur/uracil and oral calcium folinate in colorectal cancer].
    Internist (Berl); 1998 Dec; 39(12 Suppl Tegafur):1-8. PubMed ID: 10101693
    [No Abstract]   [Full Text] [Related]  

  • 48. [Radiotherapy in combination with low-dose chemotherapy in locally advanced head and neck cancer].
    Nagy B; Molnár J; Rovó L; Paczona R; Thurzó L
    Magy Onkol; 2004; 48(2):145-9. PubMed ID: 15351810
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Atorvastatin-induced dermatomyositis.
    Oztas M; Ugurlu S; Aydin O
    Rheumatol Int; 2017 Jul; 37(7):1217-1219. PubMed ID: 28238074
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group.
    Ohtsu A; Baba H; Sakata Y; Mitachi Y; Horikoshi N; Sugimachi K; Taguchi T
    Br J Cancer; 2000 Jul; 83(2):141-5. PubMed ID: 10901361
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.
    Tsuchiya T; Nagayasu T; Yamasaki N; Matsumoto K; Miyazaki T; Tagawa T; Nakamura A; Minami H; Taniguchi H; Akamine S; Hisano H; Taniguchi Y
    Clin Lung Cancer; 2012 Nov; 13(6):464-9. PubMed ID: 22424872
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outpatient chemotherapy with S-1 for recurrent head and neck cancer.
    Yamashita T; Shinden S; Watabe T; Shiotani A
    Anticancer Res; 2009 Feb; 29(2):577-81. PubMed ID: 19331206
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
    Takashima T; Mukai H; Hara F; Matsubara N; Saito T; Takano T; Park Y; Toyama T; Hozumi Y; Tsurutani J; Imoto S; Watanabe T; Sagara Y; Nishimura R; Shimozuma K; Ohashi Y;
    Lancet Oncol; 2016 Jan; 17(1):90-8. PubMed ID: 26617202
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Factors predicting the response to oral fluoropyrimidine drugs: a phase II trial on the individualization of postoperative adjuvant chemotherapy using oral fluorinated pyrimidines in stage III colorectal cancer treated by curative resection (ACT-01 Study).
    Mori T; Ohue M; Takii Y; Hashizume T; Kato T; Kotake K; Sato T; Tango T
    Oncol Rep; 2013 Feb; 29(2):437-44. PubMed ID: 23232805
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [A case of liver metastasis of gastric cancer responding well to TS-1].
    Niinobu T; Yamamoto M; Taniguchi M; Kotobuki T; Otsuka A
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1674-7. PubMed ID: 15553680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Biochemical modulation by leucovorin of the antineoplastic effect of fluorofur in disseminated colorectal cancer].
    Manziuk LV; Perevodchikova NI; Gorbunova VA; Luk'ianchenko AB; Abramova NA
    Vopr Onkol; 1996; 42(3):33-6. PubMed ID: 8801738
    [No Abstract]   [Full Text] [Related]  

  • 57. Raynaud's phenomenon possibly induced by a compund drug of tegafur and uracil.
    Seishima M; Izumi T; Kanoh H
    Eur J Dermatol; 2000; 10(1):55-8. PubMed ID: 10694301
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
    Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
    Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
    N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Feasibility study of S-1 for resectable gastric cancer with peritoneal seeding.
    Fujitani K; Tsujinaka T; Hirao M
    Hepatogastroenterology; 2003; 50(51):889-92. PubMed ID: 12828112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.